Cue Biopharma Stock Analysis

Cue Stock Analysis Notes

About 19.0% of the company shares are held by institutions such as insurance companies. The book value of Cue Biopharma was currently reported as 0.42. The company recorded a loss per share of 0.95. Cue Biopharma had not issued any dividends in recent years. Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cue Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people. For more info on Cue Biopharma please contact JD MSc at 617 949 2680 or go to https://www.cuebiopharma.com.

Cue Biopharma Investment Alerts

Cue Biopharma Upcoming and Recent Events

Cue Largest EPS Surprises

View All Earnings Estimates

Cue Stock Institutional Investors

Note, although Cue Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cue Market Capitalization

The company currently falls under 'Micro-Cap' category with a total capitalization of 82.99 M.

Cue Profitablity

Management Efficiency

Cue Biopharma has Return on Asset of (0.5018) % which means that on every $100 spent on assets, it lost $0.5018. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.3115) %, meaning that it generated no profit with money invested by stockholders. Cue Biopharma's management efficiency ratios could be used to measure how well Cue Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to -1. In addition to that, Return On Capital Employed is expected to decline to -1.42. The current year's Debt To Assets is expected to grow to 0.23, whereas Total Assets are forecasted to decline to about 66.4 M.

Technical Drivers

As of the 26th of February, Cue Biopharma shows the risk adjusted performance of 0.0635, and Mean Deviation of 5.17. Cue Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cue Biopharma potential upside, skewness, as well as the relationship between the jensen alpha and coefficient of variation to decide if Cue Biopharma is priced correctly, providing market reflects its regular price of 1.31 per share. Given that Cue Biopharma is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Cue Biopharma Price Movement Analysis

Cue Biopharma Insider Trading Activities

Cue Biopharma Outstanding Bonds

Cue Biopharma Predictive Daily Indicators

Cue Biopharma Forecast Models

Cue Biopharma's time-series forecasting models are one of many Cue Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cue Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cue Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cue shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cue Biopharma. By using and applying Cue Stock analysis, traders can create a robust methodology for identifying Cue entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cue analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cue analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cue Biopharma stock analysis indicators help investors evaluate how Cue Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cue Biopharma shares will generate the highest return on investment. By understating and applying Cue Biopharma stock analysis, traders can identify Cue Biopharma position entry and exit signals to maximize returns.

When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.